Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
21 mai 2024 11h30 HE
|
Pharming Group N.V.
Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today,...
Pharming Group to participate in May investor conference
20 mai 2024 02h00 HE
|
Pharming Group N.V.
Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
15 mai 2024 01h00 HE
|
Pharming Group N.V.
THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE...
Pharming Group reports first quarter 2024 financial results and provides business update
08 mai 2024 01h00 HE
|
Pharming Group N.V.
First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST®RUCONEST® revenues...
Pharming Group to report first quarter 2024 financial results on May 8
24 avr. 2024 02h00 HE
|
Pharming Group N.V.
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial...
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
24 avr. 2024 01h00 HE
|
Pharming Group N.V.
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the...
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
19 avr. 2024 12h43 HE
|
Pharming Group N.V.
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. ...
Pharming Group announces the placement of €100 million convertible bonds due 2029
18 avr. 2024 09h04 HE
|
Pharming Group N.V.
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. ...
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
18 avr. 2024 02h00 HE
|
Pharming Group N.V.
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. ...
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
08 avr. 2024 01h00 HE
|
Pharming Group N.V.
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming...